TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Date: 13-08-2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai — 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2026.

Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2026 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on **Thursday, 13th August, 2026** at **Shop No 1 Building Name: Shivprasad Harihar Singh Compound, Block Sector: Jogeshwari East, Road: Caves Road. Pratap Nagar -Mumbai, Maharashtra, 400060** at 3:00 p.m., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Rawandale

Tejnaksh Healthcare Limited MUMBAI

Dr. Ashish V. Rawandale
Managing Director
DIN: - 02005733

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Tejnaksh Healthcare Limited for the Quarter ended June 30, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to,
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Company') for the quarter ended June 30, 2026 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations)

2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended March 31, 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

MAHESHWARI & CO. FRN: 105834W MUMBAI Chartered Accountants

Vikas Asawa
(Partner)
Membership No.: 172133
UDIN:26172133GMUTTI9461

Place: Mumbai
Date: August 13, 2026

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN: L85100MH2008PLC179034)
Statement of Standalone Financial Results for quarter ended June 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	Quarter Ended			Year Ended
	Jun-26 Unaudited	Mar-26 Audited	Jun-25 Unaudited	Mar-26 Audited
REVENUE				
Revenue from operations (net)	184.29	177.05	178.06	717.72
Other income	9.03	14.79	8.43	37.42
Total Income	**193.32**	**191.84**	**186.48**	**755.14**
EXPENSES				
Cost of Materials Consumed	0.20	4.35	0.07	4.79
Purchases of stock-in-trade	13.99	11.94	11.89	43.69
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(2.08)	(11.79)	(5.40)	(3.07)
Employee benefits expense	14.69	15.45	18.47	77.69
Finance costs	1.19	0.68	4.33	13.17
Depreciation and amortization expense	32.58	33.08	32.81	131.32
Other expenses	87.66	76.58	79.24	308.99
Total Expenses	**148.23**	**130.29**	**141.41**	**576.58**
Profit before Exceptional Items & Tax	**45.10**	**61.55**	**45.07**	**178.56**
Exceptional Items	-	-	-	-
Profit/(Loss) Before Tax	**45.10**	**61.55**	**45.07**	**178.56**
Tax expense:				
Current tax	11.82	22.03	7.51	43.19
Deferred tax	4.17	(10.89)	3.84	(2.61)
Profit /(Loss) for the period/year	**29.11**	**50.41**	**33.73**	**137.98**
Other Comprehensive Income/(Loss)				
Items that will not be reclassified to profit or loss :				
Remeasurement of defined employee benefit plans	(0.13)	(0.05)	0.34	0.98
Income tax effect on above	0.03	0.01	(0.09)	(0.25)
Total Other Comprehensive income for the year, net of tax	**(0.10)**	**(0.04)**	**0.25**	**0.73**
Total Comprehensive Income (Net of Tax) for the Period/Year	**29.01**	**50.37**	**33.98**	**138.71**
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the period				1,663.87
Earnings per share (EPS)				
Basic and Diluted Earing Per Share	0.14	0.39	0.17	0.68
		Not Annualized		Yearly

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Standalone Financial Results for the period ended June 30, 2026

1. The above standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13, 2026. The Statutory Auditors have carried out limited review of the unaudited standalone interim financial results for the quarter ended June 30, 2026 and have issued an unmodified conclusion on the same.

2. The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") 34 – Interim Financial Reporting as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. The figures of the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended December 31, 2025 which were subjected to limited review by the statutory auditors.

4. The Company's business activity primarily falls within a single reportable business segment namely " Medical and Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".

5. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from November 21, 2025.

Tejnaksh Healthcare Limited
MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

The Company has remeasured the gratuity liability as at June 30, 2026 and March 31, 2026 in accordance with the provisions of the New Labour Codes. Based on such remeasurement, there was a reversal of gratuity liability, which has been recognized as Other Income in the current reporting period. Further, no material additional liability in respect of compensated absences and provident fund has arisen pursuant to the aforesaid codes. The Government is in the process of notifying the relevant rules under the New Labour Codes, and the consequential impact, if any, will be evaluated and accounted for in accordance with the applicable accounting standards in the period in which such rules are notified.

6. Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, wherever applicable, which are not material.

For and on behalf of Board of Directors of
Tejnaksh Healthcare Limited

Rawandale

Dr. Ashish V. Rawandale
Managing Director
DIN: 02005733

Tejnaksh Healthcare Limited
MUMBAI

Date: August 13, 2026
Place: Mumbai

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Tejnaksh Healthcare Limited for the quarter ended June 30, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Parent') and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 (the 'Statement'), attached herewith, being submitted by the Parent pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations).

2. This Statement which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
   a. Holding Company: Tejnaksh Healthcare Limited
   b. Subsidiary: Tej Vedaant Healthcare Private Limited

5. Attention is drawn to the fact that the figures for the three months ended March 31, 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

MAHESHWARI & CO.
FRN:105834W
MUMBAI
Chartered Accountants

6. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measuresment principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

Vikas Asawa
(Partner)
Membership No.: 172133
UDIN:26172133EORDUW1583

MAHESHWARI & CO.
FRN:105834W
MUMBAI
Chartered Accountants

Place: Mumbai
Date: August 13, 2026

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN : L85100MH2008PLC179034)
Statement of Consolidated Financial Results for quarter ended June 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	Quarter ended			Year ended
	Jun-26	Mar-26	Jun-25	Mar-26
	Unaudited	Audited	Unaudited	Audited
REVENUE				
Revenue from operations (net)	265.39	255.29	263.97	1,078.69
Other income	9.74	13.63	9.42	39.30
Total Income	**275.13**	**268.92**	**273.39**	**1,117.99**
EXPENSES				
Cost of Materials Consumed	0.20	4.35	0.07	4.79
Purchases of stock-in-trade	29.51	24.03	25.14	102.16
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(4.96)	(6.33)	1.49	(5.17)
Employee benefits expense	29.06	31.06	33.46	139.28
Finance costs	1.19	(2.93)	5.34	9.56
Depreciation and amortization expense	35.45	35.91	35.67	142.81
Other expenses	142.62	130.90	143.72	559.94
Total Expenses	**233.07**	**216.99**	**244.89**	**953.37**
Profit/(Loss) before Exceptional Items & Tax	**42.06**	**51.93**	**28.50**	**164.62**
Exceptional Items	-	-	-	-
Profit/(Loss) Before Tax	**42.06**	**51.93**	**28.50**	**164.62**
Tax expense:				
Current tax	11.82	22.03	7.51	43.19
Deferred tax	4.17	(4.96)	(0.28)	3.32
Profit/(Loss) for the period/year	**26.07**	**34.86**	**21.27**	**118.11**
Items that will not be reclassified to profit or loss :				
Remeasurement of defined employee benefit plans	(0.20)	(0.64)	0.63	1.26
Income tax credit(expense) relating to above items	0.03	0.23	(0.16)	(0.25)
Other Comprehensive Income/(Loss) for the year, net of tax	**(0.17)**	**(0.41)**	**0.47**	**1.01**
TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	**25.90**	**34.45**	**21.74**	**119.12**
Profit/(Loss) for the year attributable to:				
Equity holders of the parent	27.08	36.10	25.04	122.82
Non-controlling Interests	(1.01)	(1.23)	(3.77)	(4.71)
Other Comprehensive Income/(Loss) for the year attributable to:				
Equity holders of the parent	(0.15)	(0.26)	0.42	0.94
Non-controlling Interests	(0.02)	(0.15)	0.05	0.07
Total Comprehensive Income/(Loss) for the year attributable to:				
Equity holders of the parent	26.93	35.84	25.93	123.76
Non-controlling Interests	(1.03)	(1.38)	(4.19)	(4.64)
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous year				1,699.16
Earnings per share (EPS)				
Basic and Diluted Earing Per Share	0.13	0.17	0.12	0.61
		Not Annualized		Yearly

Tejnaksh Healthcare Limited
MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Consolidated Financial Results for the period ended June 30, 2026

1. The above Consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13, 2026. The Statutory Auditors have carried out limited review of the unaudited consolidated interim financial results for the quarter ended June 30, 2026 and have issued an unmodified conclusion on the same.

2. The above consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") 34 – Interim Financial Reporting as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. The accompanying consolidated financial results include the financial results of the subsidiary company, Tej Vedaant Healthcare Private Limited.

4. The figures of the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended December 31, 2025 which were subjected to limited review by the statutory auditors.

5. The Company's business activity primarily falls within a single reportable business segment namely "Medical and Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".

6. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the 'New Labour Codes'). These codes have been made effective from November 21, 2025.

Tejnaksh Healthcare Limited
MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

The Group has remeasured the gratuity liability as at June 30, 2026 and March 31, 2026 in accordance with the provisions of the New Labour Codes. Based on such remeasurement, there was a reversal of gratuity liability, which has been recognized as Other Income in the current reporting period. Further, no material additional liability in respect of compensated absences and provident fund has arisen pursuant to the aforesaid codes. The Government is in the process of notifying the relevant rules under the New Labour Codes, and the consequential impact, if any, will be evaluated and accounted for in accordance with the applicable accounting standards in the period in which such rules are notified.

7. Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, wherever applicable, which are not material.

For and on behalf of Board of Directors of

Tejnaksh Healthcare Limited

Rawandale

Tejnaksh Healthcare Limited MUMBAI

Dr. Ashish V. Rawandale
Managing Director
DIN: 02005733

Date: August 13, 2026
Place: Mumbai